Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 10:38 AM ET

No photo found yet (own website and image search run after this page is viewed)

David Mott

Named as an officer, director or promoter on SEC Form D filings · MD, CA, MA, Netherlands (as filed: P7) · May 20, 2010 → Mar 29, 2019

24deals (issuers)

$5.81Breported sold

562investors

50Form D filings

2010–2019years on file

Follow this person Look further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:21 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

David Mott is listed as an executive officer and director on 50 SEC Form D filings by 24 issuers between Apr 2009 and Dec 2019. Largest by amount reported sold: NEW ENTERPRISE ASSOCIATES 13 LP (Baltimore, MD — pooled investment fund — 2009; $2.46B reported sold to 187 investors), New Enterprise Associates 14, L.P. (Timonium, MD — pooled investment fund — 2012; $2.08B reported sold to 146 investors), NEA 15 Opportunity Fund, L.P. (Timonium, MD — pooled investment fund — 2015; $350M reported sold to 9 investors), TESARO, Inc. (Waltham, MA — pharmaceuticals — 2010–2016; $155M reported sold to 17 investors), NEA BH SPV, L.P. (Timonium, MD — pooled investment fund — 2019; $129.3M reported sold to 17 investors) and 19 more (all listed below).

What this means That is a lot of deals — 24 separate companies raised money with this person listed as executive officer and director, over about 10 years. Across those companies the filings report $5.81B sold in total.

Listed alongside Sara Nayeem (14 shared filings), Beth Seidenberg (10 shared filings), Forest Baskett (10 shared filings), Scott Sandell (10 shared filings), Gordon Ringold (9 shared filings) and 153 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around David. Each name links to their own page.

The issuers belong to 3 sponsor groups: Nea (19 issuers, $10.96B reported sold, 2009–2025), Cydan (3 issuers, $22.3M reported sold, 2013–2019) and Zosano Pharma (3 issuers, $12.6M reported sold, 2010–2016).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 30 bankruptcy cases matching the name listed in Key records below.

What this means 30 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 50 public filings for David Mott and found 11 differences, 3 worth asking the sponsor about: 20 bankruptcy cases name the subject or team members; David Mott appears on 7 deals that stopped filing before reaching their target; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for David Mott has not run yet — it is #31,806 of 58,013 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 649 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:21 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched David Mott..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

30 cases: 1 open, 29 closed (disposition not in docket feed)

David W. Mott, Jr. open

United States Bankruptcy Court, D. Connecticut · No. 25-20469 · Filed May 6, 2025

Role of David W. Mott, Jr.: Debtor · Outcome: Open — no termination date on the docket (bulk snapshot 2026-09-30) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in CT (not a filing state)

David B Mott closed

United States Bankruptcy Court, E.D. Louisiana · No. 20-11711 · Filed Oct 2, 2020 · Closed Jan 8, 2021

Role of David B Mott: Debtor · Outcome: Case closed 2021-01-08 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in LA (not a filing state)

David C Mott and Brenda J Mott closed

United States Bankruptcy Court, M.D. Florida · No. 8:14-bk-00782 · Filed Jan 24, 2014 · Closed May 20, 2020

Role of David C Mott and Brenda J Mott: Debtor · Outcome: Case closed 2020-05-20 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in FL (not a filing state)

David L. Mott and Deborah Lee Mott closed

United States Bankruptcy Court, E.D. Michigan · No. 13-32952 · Filed Aug 28, 2013 · Closed Apr 28, 2014

Role of David L. Mott and Deborah Lee Mott: Debtor · Outcome: Case closed 2014-04-28 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in MI (not a filing state)

David J. Mott and Cynthia L. Mott closed

United States Bankruptcy Court, E.D. Pennsylvania · No. 12-19082 · Filed Sep 26, 2012 · Closed Jun 25, 2013

Role of David J. Mott and Cynthia L. Mott: Debtor · Outcome: Case closed 2013-06-25 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (PA)

David J. Mott and Cynthia L. Mott closed

United States Bankruptcy Court, E.D. Pennsylvania · No. 12-10557 · Filed Jan 23, 2012 · Closed Jan 28, 2013

Role of David J. Mott and Cynthia L. Mott: Debtor · Outcome: Case closed 2013-01-28 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (PA)

David E. Mott closed

United States Bankruptcy Court, C.D. California · No. 6:11-bk-44104 · Filed Nov 3, 2011 · Closed Feb 14, 2012

Role of David E. Mott: Debtor · Outcome: Case closed 2012-02-14 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (CA)

David J. Mott and Cynthia L. Mott closed

United States Bankruptcy Court, E.D. Pennsylvania · No. 11-12295 · Filed Mar 28, 2011 · Closed Jan 9, 2012

Role of David J. Mott and Cynthia L. Mott: Debtor · Outcome: Case closed 2012-01-09 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (PA)

David J. Mott, Jr. and Michelle L. Mott closed

United States Bankruptcy Court, N.D. Ohio · No. 09-44439 · Filed Nov 23, 2009 · Closed Mar 29, 2010

Role of David J. Mott, Jr.: Debtor · Outcome: Case closed 2010-03-29 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in OH (not a filing state)

David C. Mott closed

United States Bankruptcy Court, E.D. Pennsylvania · No. 09-12950 · Filed Apr 22, 2009 · Closed Aug 21, 2009

Role of David C. Mott: Debtor · Outcome: Case closed 2009-08-21 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (PA)

David J Mott closed

United States Bankruptcy Court, N.D. Alabama · No. 07-71600 · Filed Sep 12, 2007 · Closed Oct 25, 2011

Role of David J Mott: Debtor · Outcome: Case closed 2011-10-25 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in AL (not a filing state)

David M. Mott closed

United States Bankruptcy Court, D. New Jersey · No. 07-11316 · Filed Jan 31, 2007 · Closed May 31, 2007

Role of David M. Mott: Debtor · Outcome: Case closed 2007-05-31 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (NJ)

David E. Mott closed

United States Bankruptcy Court, D. Colorado · No. 05-37810 · Filed Sep 30, 2005 · Closed Feb 3, 2006

Role of David E. Mott: Debtor · Outcome: Case closed 2006-02-03 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (CO)

David K Mott closed

United States Bankruptcy Court, M.D. Florida · No. 2:05-bk-15848 · Filed Aug 10, 2005 · Closed Dec 8, 2008

Role of David K Mott: Debtor · Outcome: Case closed 2008-12-08 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in FL (not a filing state)

David B. Mott and Ellen A. Mott closed

United States Bankruptcy Court, W.D. New York · No. 2-05-22127 · Filed May 2, 2005 · Closed Oct 24, 2008

Role of David B. Mott and Ellen A. Mott: Debtor · Outcome: Case closed 2008-10-24 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in NY (not a filing state)

David C. Mott and Karen J. Mott closed

United States Bankruptcy Court, D. Massachusetts · No. 04-46382 · Filed Nov 12, 2004 · Closed Apr 26, 2006

Role of David C. Mott and Karen J. Mott: Debtor · Outcome: Case closed 2006-04-26 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (MA)

David C. Mott and Karen J. Mott closed

United States Bankruptcy Court, D. Massachusetts · No. 04-43716 · Filed Jun 28, 2004 · Closed Oct 28, 2004

Role of David C. Mott and Karen J. Mott: Debtor · Outcome: Case closed 2004-10-28 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (MA)

David G. Mott and Florence M. Kuenzler closed

United States Bankruptcy Court, D. Colorado · No. 03-30006 · Filed Oct 7, 2003 · Closed May 28, 2004

Role of David G. Mott and Florence M. Kuenzler: Debtor · Outcome: Case closed 2004-05-28 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (CO)

David S. Mott and Ruth E. Mott closed

United States Bankruptcy Court, W.D. Pennsylvania · No. 03-31429 · Filed Sep 11, 2003 · Closed Sep 12, 2003

Role of David S. Mott and Ruth E. Mott: Debtor · Outcome: Case closed 2003-09-12 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (PA)

David S. Mott and Ruth E. Mott closed

United States Bankruptcy Court, W.D. Pennsylvania · No. 03-12219 · Filed Sep 11, 2003 · Closed Jan 8, 2004

Role of David S. Mott and Ruth E. Mott: Debtor · Outcome: Case closed 2004-01-08 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (PA)

David V.S. Mott and Vickie L Mott closed

United States Bankruptcy Court, W.D. Virginia · No. 03-02939 · Filed Jul 7, 2003 · Closed Oct 7, 2003

Role of David V.S. Mott and Vickie L Mott: Debtor · Outcome: Case closed 2003-10-07 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in VA (not a filing state)

David J. Mott closed

United States Bankruptcy Court, M.D. Florida · No. 3:03-bk-03965 · Filed Apr 21, 2003 · Closed Feb 26, 2004

Role of David J. Mott: Debtor · Outcome: Case closed 2004-02-26 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in FL (not a filing state)

David R. Mott closed

United States Bankruptcy Court, D. Maryland · No. 01-17153 · Filed May 31, 2001 · Closed Oct 10, 2002

Role of David R. Mott: Debtor · Outcome: Case closed 2002-10-10 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (MD)

David C. Mott and Karen J. Mott closed

United States Bankruptcy Court, D. Massachusetts · No. 97-41771 · Filed Mar 19, 1997 · Closed Jul 9, 1997

Role of David C. Mott and Karen J. Mott: Debtor · Outcome: Case closed 1997-07-09 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (MA)

David J. Mott and Cynthia L. Mott closed

United States Bankruptcy Court, M.D. Pennsylvania · No. 1:96-bk-02751 · Filed Sep 27, 1996 · Closed May 1, 2001

Role of David J. Mott and Cynthia L. Mott: Debtor · Outcome: Case closed 2001-05-01 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (PA)

David K Mott closed

United States Bankruptcy Court, E.D. New York · No. 1-96-14279 · Filed May 9, 1996 · Closed Nov 8, 2001

Role of David K Mott: Debtor · Outcome: Case closed 2001-11-08 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in NY (not a filing state)

David J Mott and LINDA L. MOTT closed

United States Bankruptcy Court, N.D. Alabama · No. 96-70270 · Filed Feb 6, 1996 · Closed Dec 9, 1998

Role of David J Mott and LINDA L. MOTT: Debtor · Outcome: Case closed 1998-12-09 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in AL (not a filing state)

David J Mott and Trudy A Mott closed

United States Bankruptcy Court, C.D. California · No. 8:90-bk-08075 · Filed Nov 13, 1990 · Closed Sep 18, 1995

Role of David J Mott and Trudy A Mott: Debtor · Outcome: Case closed 1995-09-18 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in the person's filing state (CA)

David E. Mott and Martha Mott closed

United States Bankruptcy Court, D. Nebraska · No. 87-80550 · Filed Feb 26, 1987 · Closed Jun 2, 1992

Role of David E. Mott and Martha Mott: Debtor · Outcome: Case closed 1992-06-02 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets)

David W. Mott and Sherrill A. Mott closed

United States Bankruptcy Court, D. Connecticut · No. 86-20030 · Filed Jan 10, 1986 · Closed Jun 30, 1987

Role of David W. Mott and Sherrill A. Mott: Debtor · Outcome: Case closed 1987-06-30 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same full name (a name found in 55 federal dockets); court in CT (not a filing state)

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:21 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

11 differences found between the filings for David Mott — 3 worth asking about (compared 50 filings on Oct 24, 2026)

Worth asking · Nov 13, 1990 – Jun 25, 2013

20 bankruptcy cases name the subject or team members

Bankruptcy case: David J. Mott and Cynthia L. Mott — filed Sep 26, 2012 · Bankruptcy case: David J. Mott and Cynthia L. Mott — filed Jan 23, 2012 · Bankruptcy case: David E. Mott — filed Nov 3, 2011 · Bankruptcy case: David J. Mott and Cynthia L. Mott — filed Mar 28, 2011 · Bankruptcy case: David C. Mott — filed Apr 22, 2009 · and 15 more

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗Docket · United States Bankruptcy Court, C.D. California ↗Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗

Sources

Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗ (Sep 26, 2012)
Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗ (Jan 23, 2012)
Docket · United States Bankruptcy Court, C.D. California ↗ (Nov 3, 2011)
Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗ (Mar 28, 2011)
Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗ (Apr 22, 2009)
Docket · United States Bankruptcy Court, D. New Jersey ↗ (Jan 31, 2007)
Docket · United States Bankruptcy Court, D. Massachusetts ↗ (Nov 12, 2004)
Docket · United States Bankruptcy Court, D. Colorado ↗ (Sep 30, 2005)

Worth asking · May 1, 2012 – Mar 1, 2019

David Mott appears on 7 deals that stopped filing before reaching their target

New Enterprise Associates 17, L.P. (last filing Mar 1, 2019; $0 sold of $3,600,000,000); Tiburio Therapeutics Inc. (last filing Jan 8, 2019; $5,000,001 sold of $31,000,001); Cydan II, Inc. (last filing Oct 11, 2017; $10,666,666 sold of $34,000,000); New Enterprise Associates 16, L.P. (last filing Jan 17, 2017; $0 sold of $3,000,000,000); New Enterprise Associates 15, L.P. (last filing Jan 13, 2015; $0 sold of $2,500,000,000); Cydan, LLC (last filing Oct 2, 2013; $6,601,336 sold of $26,333,836); and 1 more. Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

New Enterprise Associates 17, L.P. — PartnerFacts page ↗Tiburio Therapeutics Inc. — PartnerFacts page ↗Cydan II, Inc. — PartnerFacts page ↗New Enterprise Associates 16, L.P. — PartnerFacts page ↗

Sources

New Enterprise Associates 17, L.P. — PartnerFacts page ↗ (Mar 1, 2019)
Tiburio Therapeutics Inc. — PartnerFacts page ↗ (Jan 8, 2019)
Cydan II, Inc. — PartnerFacts page ↗ (Oct 11, 2017)
New Enterprise Associates 16, L.P. — PartnerFacts page ↗ (Jan 17, 2017)
New Enterprise Associates 15, L.P. — PartnerFacts page ↗ (Jan 13, 2015)
Cydan, LLC — PartnerFacts page ↗ (Oct 2, 2013)

Worth asking · Jun 18, 2009 – Jan 8, 2019

6 Form Ds were filed more than 15 days after the first sale

Form D filed 146 days after the first sale — Sagimet Biosciences Inc. · Form D filed 285 days after the first sale — Zosano Pharma Inc · Form D filed 19 days after the first sale — Tiburio Therapeutics Inc. · Form D filed 18 days after the first sale — Sagimet Biosciences Inc. · Form D filed 17 days after the first sale — ARDELYX, INC. · and 1 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Mar 17, 2015 ↗Sagimet Biosciences Inc. — PartnerFacts page ↗Form D · Mar 30, 2010 ↗Zosano Pharma Inc — PartnerFacts page ↗

Sources

Form D · Mar 17, 2015 ↗ (Mar 17, 2015)
Sagimet Biosciences Inc. — PartnerFacts page ↗ (Jan 5, 2021)
Form D · Mar 30, 2010 ↗ (Mar 30, 2010)
Zosano Pharma Inc — PartnerFacts page ↗ (Sep 23, 2011)
Form D · Jan 8, 2019 ↗ (Jan 8, 2019)
Tiburio Therapeutics Inc. — PartnerFacts page ↗ (Jan 8, 2019)
Form D · Jul 5, 2016 ↗ (Jul 5, 2016)
Form D · Jun 22, 2015 ↗ (Jun 22, 2015)

Note · Dec 23, 2008 – Apr 16, 2019

27 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Complexa Inc. (latest filing Apr 16, 2019) · No amendment in the last 12 months on an offering that may still be open — Enliven Therapeutics, Inc. (latest filing Mar 29, 2019) · No amendment in the last 12 months on an offering that may still be open — Sagimet Biosciences Inc. (latest filing Feb 25, 2019) · No amendment in the last 12 months on an offering that may still be open — Tiburio Therapeutics Inc. (latest filing Jan 8, 2019) · No amendment in the last 12 months on an offering that may still be open — Cydan II, Inc. (latest filing Oct 11, 2017) · and 22 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Apr 16, 2019 ↗Complexa Inc. — PartnerFacts page ↗Form D · Mar 29, 2019 ↗Enliven Therapeutics, Inc. — PartnerFacts page ↗

Sources

Form D · Apr 16, 2019 ↗ (Apr 16, 2019)
Complexa Inc. — PartnerFacts page ↗ (Apr 16, 2019)
Form D · Mar 29, 2019 ↗ (Mar 29, 2019)
Enliven Therapeutics, Inc. — PartnerFacts page ↗ (Apr 3, 2024)
Form D · Feb 25, 2019 ↗ (Feb 25, 2019)
Sagimet Biosciences Inc. — PartnerFacts page ↗ (Jan 5, 2021)
Form D · Jan 8, 2019 ↗ (Jan 8, 2019)
Tiburio Therapeutics Inc. — PartnerFacts page ↗ (Jan 8, 2019)

Note · Mar 3, 2015 – Mar 1, 2016

David Mott's role changed at Mersana Therapeutics, Inc.: executive officer, director → director

The Mar 3, 2015 filing lists David Mott as executive officer, director; the Mar 1, 2016 Form D/A lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Mar 3, 2015 ↗Form D/A · Mar 1, 2016 ↗David Mott — PartnerFacts page ↗Mersana Therapeutics, Inc. — PartnerFacts page ↗

Sources

Form D · Mar 3, 2015 ↗ (Mar 3, 2015)
Form D/A · Mar 1, 2016 ↗ (Mar 1, 2016)
David Mott — PartnerFacts page ↗
Mersana Therapeutics, Inc. — PartnerFacts page ↗ (Jun 24, 2016)

Note · Oct 9, 2013 – Apr 8, 2014

David Mott's role changed at Mersana Therapeutics, Inc.: director → executive officer, director

The Oct 9, 2013 filing lists David Mott as director; the Apr 8, 2014 Form D/A lists executive officer, director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Oct 9, 2013 ↗Form D/A · Apr 8, 2014 ↗David Mott — PartnerFacts page ↗Mersana Therapeutics, Inc. — PartnerFacts page ↗

Sources

Form D · Oct 9, 2013 ↗ (Oct 9, 2013)
Form D/A · Apr 8, 2014 ↗ (Apr 8, 2014)
David Mott — PartnerFacts page ↗
Mersana Therapeutics, Inc. — PartnerFacts page ↗ (Jun 24, 2016)

Note · Mar 15, 2011 – Sep 2, 2016

6 offerings changed their target amount between filings

Offering amount lowered between filings — XTuit Pharmaceuticals, Inc. · Offering amount changed between filings — XTuit Pharmaceuticals, Inc. · Offering amount changed between filings — Mersana Therapeutics, Inc. · Offering amount changed between filings — Cydan, LLC · Offering amount changed between filings — New Enterprise Associates 14, L.P. · and 1 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D/A (earlier) · Jun 11, 2015 ↗Form D/A (later) · Sep 2, 2016 ↗XTuit Pharmaceuticals, Inc. — PartnerFacts page ↗Form D (earlier) · Dec 5, 2014 ↗

Sources

Form D/A (earlier) · Jun 11, 2015 ↗ (Jun 11, 2015)
Form D/A (later) · Sep 2, 2016 ↗ (Sep 2, 2016)
XTuit Pharmaceuticals, Inc. — PartnerFacts page ↗ (Sep 2, 2016)
Form D (earlier) · Dec 5, 2014 ↗ (Dec 5, 2014)
Form D/A (later) · Jun 11, 2015 ↗ (Jun 11, 2015)
Form D (earlier) · Oct 9, 2013 ↗ (Oct 9, 2013)
Form D/A (later) · Apr 8, 2014 ↗ (Apr 8, 2014)
Mersana Therapeutics, Inc. — PartnerFacts page ↗ (Jun 24, 2016)

Note · Apr 27, 2009 – Mar 30, 2010

David Mott is written 2 different ways on the filings

listed as "David Mott" on 38 filings (from Apr 27, 2009), and "David M. Mott" on 12 filings (from Mar 30, 2010).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D/A · Apr 27, 2009 ↗Form D · Mar 30, 2010 ↗David Mott — PartnerFacts page ↗

Sources

Form D/A · Apr 27, 2009 ↗ (Apr 27, 2009)
Form D · Mar 30, 2010 ↗ (Mar 30, 2010)
David Mott — PartnerFacts page ↗

Note · May 20, 2010 – Mar 10, 2016

Reported revenue range changed between filings — TESARO, Inc.

"Decline to Disclose" (May 20, 2010); then "$1 - $1,000,000" (Mar 10, 2016).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · May 20, 2010 ↗Form D · Mar 10, 2016 ↗TESARO, Inc. — PartnerFacts page ↗

Sources

Form D · May 20, 2010 ↗ (May 20, 2010)
Form D · Mar 10, 2016 ↗ (Mar 10, 2016)
TESARO, Inc. — PartnerFacts page ↗ (Apr 18, 2016)

Note · Jul 22, 2009 – Apr 16, 2019

6 address changes between filings

Address moved from Radnor, PA to Chevy Chase, MD — Complexa Inc. · Address moved from Menlo Park, CA to Campbell, CA — Sagimet Biosciences Inc. · Address moved from Lincoln, MA to Cambridge, MA — Cydan, LLC · Address moved from Bedminster, NJ to Princeton, NJ — Omthera Pharmaceuticals, Inc. · Address moved from Palo Alto, CA to Menlo Park, CA — Sagimet Biosciences Inc. · and 1 more

What this means Businesses move. If you were told one city and the forms say another, ask which is current.

Form D · Jul 26, 2017 ↗Form D · Apr 16, 2019 ↗Complexa Inc. — PartnerFacts page ↗Form D · Jul 5, 2016 ↗

Sources

Form D · Jul 26, 2017 ↗ (Jul 26, 2017)
Form D · Apr 16, 2019 ↗ (Apr 16, 2019)
Complexa Inc. — PartnerFacts page ↗ (Apr 16, 2019)
Form D · Jul 5, 2016 ↗ (Jul 5, 2016)
Form D · Feb 25, 2019 ↗ (Feb 25, 2019)
Sagimet Biosciences Inc. — PartnerFacts page ↗ (Jan 5, 2021)
Form D · Apr 11, 2013 ↗ (Apr 11, 2013)
Form D/A · Oct 2, 2013 ↗ (Oct 2, 2013)

Note · Apr 27, 2009 – Dec 19, 2019

David Mott is listed with 4 different address states: MD, CA, MA, P7

MD on 17 filings (Apr 27, 2009 to Dec 19, 2019); CA on 13 filings (Jul 22, 2009 to Feb 25, 2019); MA on 19 filings (May 20, 2010 to Mar 29, 2019); Netherlands (as filed: P7) on 1 filing (Dec 8, 2014).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D/A · Apr 27, 2009 ↗Form D · Jul 22, 2009 ↗Form D · May 20, 2010 ↗Form D · Dec 8, 2014 ↗

Sources

Form D/A · Apr 27, 2009 ↗ (Apr 27, 2009)
Form D · Jul 22, 2009 ↗ (Jul 22, 2009)
Form D · May 20, 2010 ↗ (May 20, 2010)
Form D · Dec 8, 2014 ↗ (Dec 8, 2014)

What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

3 of 43 offerings report sales commissions totalling $5,555,000; 0 report finder's fees; 2 report proceeds to related persons totalling $1,809,721. (includes amounts the issuer reported as estimates)

Offering (latest filing)	Sales commissions	Finder's fees	To insiders	Paid to sell it	Source
Dec 19, 2019 D NEA BH SPV, L.P. File 021-355891	$0	$0	$0	None listed on this filing	EDGAR ↗
Apr 16, 2019 D Complexa Inc. File 021-337393	$0	$0	$302,000 (est.)	None listed on this filing	EDGAR ↗
Mar 29, 2019 D Enliven Therapeutics, Inc. File 021-336073	$0	$0	$0	None listed on this filing	EDGAR ↗
Mar 1, 2019 D New Enterprise Associates 17, L.P. File 021-333845	$0	$0	$0 (est.) An affiliate of the General Partner of the Issuer will receive a fee for management services based on a percentage of the Issuer's committed capital. Number of years to be paid and extent to be paid out of adjusted gross proceeds unknown at this time.	None listed on this filing	EDGAR ↗
Feb 25, 2019 D Sagimet Biosciences Inc. File 021-333505	$0	$0	$0 General corporate purposes.	None listed on this filing	EDGAR ↗
Jan 8, 2019 D Tiburio Therapeutics Inc. File 021-329946	$0	$0	$0	None listed on this filing	EDGAR ↗
Oct 11, 2017 D Cydan II, Inc. File 021-296407	$0	$0	$0	None listed on this filing	EDGAR ↗
Jul 26, 2017 D Complexa Inc. File 021-291504	$1,830,000	$0	$1,507,721 (est.)	Wedbush Securities Inc. BrokerCheck CRD 877 ↗	EDGAR ↗
Jan 17, 2017 D New Enterprise Associates 16, L.P. File 021-278594	$0	$0	$0 (est.) An affiliate of the General Partner of the Issuer will receive a fee for management services. Amount to be paid, number of years to be paid and extent to be paid out of adjusted gross proceeds unknown at this time.	None listed on this filing	EDGAR ↗
Sep 2, 2016 D/A XTuit Pharmaceuticals, Inc. File 021-229519	$0	$0	$0	None listed on this filing	EDGAR ↗
Aug 1, 2016 D ARDELYX, INC. File 021-268091	$0	$0	$0	None listed on this filing	EDGAR ↗
Jul 5, 2016 D Sagimet Biosciences Inc. File 021-266373	$0	$0	$0	None listed on this filing	EDGAR ↗
Jun 24, 2016 D Mersana Therapeutics, Inc. File 021-265754	$0	$0	$0	None listed on this filing	EDGAR ↗
Apr 21, 2016 D Enliven Therapeutics, Inc. File 021-261834	$0	$0	$0	None listed on this filing	EDGAR ↗
Apr 18, 2016 D TESARO, Inc. File 021-261523	$0	$0	$0	None listed on this filing	EDGAR ↗
Mar 10, 2016 D TESARO, Inc. File 021-258996	$0	$0	$0	None listed on this filing	EDGAR ↗
Mar 1, 2016 D/A Mersana Therapeutics, Inc. File 021-235062	$0	$0	$0	None listed on this filing	EDGAR ↗
Jun 22, 2015 D ARDELYX, INC. File 021-242234	$2,525,000	$0	$0	Leerink Partners LLC BrokerCheck CRD 39011 ↗	EDGAR ↗
Apr 15, 2015 D NEA 15 Opportunity Fund, L.P. File 021-238034	$0	$0	$0 (est.) An affiliate of the General Partner of the Issuer will receive a fee for management services. Amount to be paid, number of years to be paid and extent to be paid out of adjusted gross proceeds unknown at this time.	None listed on this filing	EDGAR ↗
Mar 17, 2015 D Sagimet Biosciences Inc. File 021-236101	$0	$0	$0	None listed on this filing	EDGAR ↗
Jan 13, 2015 D New Enterprise Associates 15, L.P. File 021-231999	$0	$0	$0 (est.) An affiliate of the General Partner of the Issuer will receive a fee for management services. Amount to be paid, number of years to be paid and extent to be paid out of adjusted gross proceeds unknown at this time.	None listed on this filing	EDGAR ↗
Dec 8, 2014 D Prosensa Holding N.V. File 021-229654	$0	$0	$0	None listed on this filing	EDGAR ↗
Oct 2, 2014 D Adaptimmune Ltd File 021-225667	$0	$0	$0	None listed on this filing	EDGAR ↗
Apr 8, 2014 D/A Mersana Therapeutics, Inc. File 021-204292	$0	$0	$0	None listed on this filing	EDGAR ↗
Oct 2, 2013 D/A Cydan, LLC File 021-194829	$0	$0	$0	None listed on this filing	EDGAR ↗
Aug 7, 2013 D Edimer Pharmaceuticals, Inc. File 021-200941	$0	$0	$0	None listed on this filing	EDGAR ↗
Jun 27, 2013 D Sagimet Biosciences Inc. File 021-198677	$0	$0	$0 The proceeds will be used for working capital.	None listed on this filing	EDGAR ↗
Feb 28, 2013 D Omthera Pharmaceuticals, Inc. File 021-192546	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 20, 2012 D/A Sagimet Biosciences Inc. File 021-169863	$0	$0	$0 The proceeds will be used for working capital.	None listed on this filing	EDGAR ↗
Sep 6, 2012 D Zyngenia, Inc. File 021-183742	$0	$0	$0 (est.)	None listed on this filing	EDGAR ↗
Aug 9, 2012 D Mersana Therapeutics, Inc. File 021-182471	$0	$0	$0	None listed on this filing	EDGAR ↗
May 9, 2012 D/A New Enterprise Associates 14, L.P. File 021-175533	$0	$0	$0 (est.) An affiliate of the General Partner will receive a fee for management services. Amount to be paid, number of years to be paid and extent to be paid out of adjusted gross proceeds unknown at this time.	None listed on this filing	EDGAR ↗
May 1, 2012 D NEA 14 Manager Fund, L.P. File 021-177519	$0	$0	$0	None listed on this filing	EDGAR ↗
Jan 6, 2012 D/A Omthera Pharmaceuticals, Inc. File 021-156702	$0	$0	$0 Some of the funds will be used as working capital and therefore to pay normal business expenses, such as salaries of officers.	None listed on this filing	EDGAR ↗
Jul 7, 2011 D ARDELYX, INC. File 021-162407	$0	$0	$0	None listed on this filing	EDGAR ↗
Jun 21, 2011 D TESARO, Inc. File 021-161614	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 23, 2010 D Zyngenia, Inc. File 021-152481	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 8, 2010 D ARDELYX, INC. File 021-151534	$0	$0	$0	None listed on this filing	EDGAR ↗
Aug 18, 2010 D Zosano Pharma Inc File 021-146604	$0	$0	$0	n/a no CRD number reported	EDGAR ↗
May 20, 2010 D TESARO, Inc. File 021-142327	$0	$0	$0	None listed on this filing	EDGAR ↗
Mar 30, 2010 D Zosano Pharma Inc File 021-110871	$0	$0	$0	N/A no CRD number reported	EDGAR ↗
Oct 16, 2009 D/A NEW ENTERPRISE ASSOCIATES 13 LP File 021-125476	$1,200,000 (est.)	$0	$0 (est.) An affiliate of the General Partner will receive a fee for management services. Amount to be paid, number of years to be paid and extent to be paid out of adjusted gross proceeds unknown at this time.	Greenhill & Co., LLC BrokerCheck CRD 40290 ↗	EDGAR ↗
Jul 22, 2009 D Sagimet Biosciences Inc. File 021-103158	$0	$0	$0 The proceeds shall be used for working capital.	None listed on this filing	EDGAR ↗

How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 24

Every issuer that named David Mott on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

Pooled Investment Fund · group: Nea

NEA BH SPV, L.P.

Timonium, MD · Dec 19, 2019

Dec 19, 2019 · D · $129,300,000 sold of $129,300,000 · 17 investors · min. $800,000 · role: Executive Officer (Manager of the General Partner.) EDGAR ↗

Raised $129.3M from 17 investors (100% of the $129.3M target) as of the latest filing. David is listed as executive officer.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals

Complexa Inc.

Berwyn, PA · Jul 26, 2017 → Apr 16, 2019 · 2 filings

Apr 16, 2019 · D · $10,999,999 sold of $28,000,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
Jul 26, 2017 · D · $40,570,421 sold of $62,570,421 · 28 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $40.6M from 28 investors (100% of the $28M target) as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals

Enliven Therapeutics, Inc.

Boulder, CO · Apr 21, 2016 → Mar 29, 2019 · 2 filings

Mar 29, 2019 · D · $44,099,096 sold of $62,998,708 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
Apr 21, 2016 · D · $6,000,000 sold of $30,999,971 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $90M from 20 investors (100% of the $63M target) as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pooled Investment Fund · group: Nea

New Enterprise Associates 17, L.P.

Timonium, MD · Mar 1, 2019

Mar 1, 2019 · D · $0 sold of $3,600,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Manager of the GP LLC.) EDGAR ↗

No sales reported yet as of the latest filing. David is listed as executive officer.

Latest filing on EDGAR ↗

Sources

Biotechnology

Sagimet Biosciences Inc.

San Mateo, CA · Jul 22, 2009 → Feb 25, 2019 · 7 filings

Feb 25, 2019 · D · $35,204,858 sold of $42,197,382 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
Jul 5, 2016 · D · $5,437,612 sold of $12,000,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 17, 2015 · D · $14,278,567 sold of $35,000,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
Jun 27, 2013 · D · $7,504,260 sold of $20,376,959 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
Dec 20, 2012 · D/A · $20,108,885 sold of $25,019,644 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
Dec 12, 2011 · D · $12,019,643 sold of $25,019,644 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
Jul 22, 2009 · D · $14,999,999 sold of $30,000,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $69M from 19 investors (100% of the $42.2M target) as of the latest filing. David is listed as director on 7 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals · group: Cydan

Tiburio Therapeutics Inc.

Cambridge, MA · Jan 8, 2019

Jan 8, 2019 · D · $5,000,001 sold of $31,000,001 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5M from 5 investors (16% of the $31M target) as of the latest filing. David is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology · group: Cydan

Cydan II, Inc.

Cambridge, MA · Oct 11, 2017

Oct 11, 2017 · D · $10,666,666 sold of $34,000,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $10.7M from 5 investors (31% of the $34M target) as of the latest filing. David is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pooled Investment Fund · group: Nea

New Enterprise Associates 16, L.P.

Timonium, MD · Jan 17, 2017

Jan 17, 2017 · D · $0 sold of $3,000,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Manager of the GP LLC) EDGAR ↗

No sales reported yet as of the latest filing. David is listed as executive officer.

Latest filing on EDGAR ↗

Sources

Pharmaceuticals

XTuit Pharmaceuticals, Inc.

Waltham, MA · Jun 11, 2015 → Sep 2, 2016 · 2 filings

Sep 2, 2016 · D/A · $22,016,999 sold of $22,016,999 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
Jun 11, 2015 · D/A · $12,008,500 sold of $22,017,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $22M from 10 investors (100% of the $22M target) as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals

ARDELYX, INC.

Fremont, CA · Dec 8, 2010 → Aug 1, 2016 · 4 filings

Aug 1, 2016 · D · $110,000,008 sold of $110,000,008 · 31 investors · min. No minimum reported · role: Director EDGAR ↗
Jun 22, 2015 · D · $77,771,627 sold of $107,996,652 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
Jul 7, 2011 · D · $17,578,665 sold of $22,283,445 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
Dec 8, 2010 · D · $5,013,694 sold of $10,027,388 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $110M from 31 investors (100% of the $110M target) as of the latest filing. David is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

Mersana Therapeutics, Inc.

Cambridge, MA · Aug 9, 2012 → Jun 24, 2016 · 6 filings

Jun 24, 2016 · D · $33,099,988 sold of $33,099,988 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 1, 2016 · D/A · $10,128,576 sold of $35,450,006 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 3, 2015 · D · $10,128,576 sold of $35,450,006 · 10 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
Apr 8, 2014 · D/A · $14,505,371 sold of $14,505,371 · 10 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
Oct 9, 2013 · D · $4,999,994 sold of $14,499,542 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
Aug 9, 2012 · D · $12,500,164 sold of $26,999,708 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $33.1M from 13 investors (100% of the $33.1M target) as of the latest filing. David is listed as director, executive officer on 6 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals

TESARO, Inc.

Waltham, MA · May 20, 2010 → Apr 18, 2016 · 4 filings

Apr 18, 2016 · D · $49,999,960 sold of $49,999,960 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 10, 2016 · D · $154,999,915 sold of $154,999,915 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
Jun 21, 2011 · D · $40,000,000 sold of $101,000,000 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
May 20, 2010 · D · $10,000,000 sold of $20,000,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $155M from 17 investors (100% of the $50M target) as of the latest filing. David is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pooled Investment Fund · group: Nea

NEA 15 Opportunity Fund, L.P.

Timonium, MD · Apr 15, 2015

Apr 15, 2015 · D · $350,000,000 sold of $350,000,000 · 9 investors · min. $7,140,000 · role: Executive Officer (Manager of the GP LLC) EDGAR ↗

Raised $350M from 9 investors (100% of the $350M target) as of the latest filing. David is listed as executive officer.

Latest filing on EDGAR ↗

Sources

Pooled Investment Fund · group: Nea

New Enterprise Associates 15, L.P.

Timonium, MD · Jan 13, 2015

Jan 13, 2015 · D · $0 sold of $2,500,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Manager of the GP LLC) EDGAR ↗

No sales reported yet as of the latest filing. David is listed as executive officer.

Latest filing on EDGAR ↗

Sources

Biotechnology

Prosensa Holding N.V.

Leiden, Netherlands (as filed: P7) · Dec 8, 2014

Dec 8, 2014 · D · $50,488,095 sold of $50,488,095 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $50.5M from 1 investor (100% of the $50.5M target) as of the latest filing. David is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

Adaptimmune Ltd

Abingdon, Oxfordshire, United Kingdom (as filed: X0) · Oct 2, 2014

Oct 2, 2014 · D · $103,809,789 sold of $103,809,789 · 22 investors · min. $1 · role: Director EDGAR ↗

Raised $103.8M from 22 investors (100% of the $103.8M target) as of the latest filing. David is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals · group: Cydan

Cydan, LLC

Cambridge, MA · Apr 11, 2013 → Oct 2, 2013 · 2 filings

Oct 2, 2013 · D/A · $6,601,336 sold of $26,333,836 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
Apr 11, 2013 · D · $3,966,336 sold of $15,793,836 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6.6M from 6 investors (25% of the $26.3M target) as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals

Edimer Pharmaceuticals, Inc.

Cambridge, MA · Aug 7, 2013

Aug 7, 2013 · D · $9,794,352 sold of $18,000,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $9.79M from 5 investors (54% of the $18M target) as of the latest filing. David is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Pharmaceuticals

Omthera Pharmaceuticals, Inc.

New Jersey, NJ · Jan 6, 2012 → Feb 28, 2013 · 2 filings

Feb 28, 2013 · D · $17,600,000 sold of Indefinite · 13 investors · min. No minimum reported · role: Director EDGAR ↗
Jan 6, 2012 · D/A · $39,009,465 sold of $49,009,465 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $39M from 13 investors as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other

Zyngenia, Inc.

Gaithersburg, MD · Dec 23, 2010 → Sep 6, 2012 · 2 filings

Sep 6, 2012 · D · $10,000,000 sold of $10,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
Dec 23, 2010 · D · $5,000,000 sold of $15,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $10M from 2 investors (100% of the $10M target) as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Pooled Investment Fund · group: Nea

New Enterprise Associates 14, L.P.

Timonium, MD · Mar 26, 2012 → May 9, 2012 · 2 filings

May 9, 2012 · D/A · $2,075,859,276 sold of $2,562,940,000 · 146 investors · min. No minimum reported · role: Director (Director of the GP LTD) EDGAR ↗
Mar 26, 2012 · D · $0 sold of $2,300,000,000 · 0 investors · min. No minimum reported · role: Director (Director of the GP LTD) EDGAR ↗

Raised $2.08B from 146 investors (81% of the $2.56B target) as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Pooled Investment Fund · group: Nea

NEA 14 Manager Fund, L.P.

Timonium, MD · May 1, 2012

May 1, 2012 · D · $0 sold of $12,877,500 · 0 investors · min. No minimum reported · role: Director (Director of the GP LTD) EDGAR ↗

No sales reported yet as of the latest filing. David is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Pharmaceuticals · group: Zosano Pharma

Zosano Pharma Inc

Fremont, CA · Mar 30, 2010 → Aug 18, 2010 · 2 filings

Aug 18, 2010 · D · $3,111,261 sold of $16,000,800 · 3 investors · min. $1 · role: Director EDGAR ↗
Mar 30, 2010 · D · $39,009,000 sold of $39,009,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $39M from 6 investors (100% of the $16M target) as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Pooled Investment Fund · group: Nea

NEW ENTERPRISE ASSOCIATES 13 LP

Baltimore, MD · Apr 27, 2009 → Oct 16, 2009 · 2 filings

Oct 16, 2009 · D/A · $2,457,680,000 sold of $2,500,000,000 · 187 investors · min. No minimum reported · role: Director (Director of the GP LTD) EDGAR ↗
Apr 27, 2009 · D/A · $2,152,425,000 sold of $2,500,000,000 · 160 investors · min. No minimum reported · role: Director (Director of the GP LTD) EDGAR ↗

Raised $2.46B from 187 investors (98% of the $2.5B target) as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

People around David 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

Management entity

NEA 14 GP, LTD

Executive Officer · 3 shared filings (2 issuers)

Listed on the same filings as David Mott. Their page shows their other deals.

Management entity

NEA Partners 14, L.P.

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

Management entity

NEA 15 GP, LLC

Executive Officer · 2 shared filings (2 issuers)

Listed on the same filings as David Mott. Their page shows their other deals.

Management entity

NEA Partners 15, L.P.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

Management entity

NEA Partners 15-OF, L.P.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

Management entity

NEA 16 GP, LLC

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

Management entity

NEA Partners 16, L.P.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

Management entity

NEA 17 GP, LLC

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

Management entity

NEA Partners 17, L.P.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

Management entity

NEA BH SPV GP, LLC

Executive Officer · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Sara Nayeem

Director · 14 shared filings (6 issuers) · also on 1 other issuer

Sara Nayeem is on 7 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Beth Seidenberg

Director · 10 shared filings (2 issuers) · also on 27 other issuers

Beth Seidenberg is on 29 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Forest Baskett

Director, Executive Officer · 10 shared filings (8 issuers) · also on 22 other issuers

Forest Baskett is on 30 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Scott Sandell

Director, Executive Officer · 10 shared filings (8 issuers) · also on 32 other issuers

Scott Sandell is on 40 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Gordon Ringold

Director · 9 shared filings (2 issuers) · also on 6 other issuers

Gordon Ringold is on 8 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Peter Sonsini

Director, Executive Officer · 8 shared filings (7 issuers) · also on 25 other issuers

Peter Sonsini is on 32 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Anthony A. Florence

Director, Executive Officer · 8 shared filings (7 issuers) · also on 12 other issuers

Anthony A. Florence is on 19 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Peter Barris

Director, Executive Officer · 8 shared filings (6 issuers) · also on 14 other issuers

Peter Barris is on 20 issuers in total — a repeat sponsor. Their page lists every one.

Image matched by name on businessinsider.com ↗

Person

Ravi Viswanathan

Director, Executive Officer · 7 shared filings (6 issuers) · also on 44 other issuers

Ravi Viswanathan is on 50 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Krishna Kolluri

Director, Executive Officer · 7 shared filings (5 issuers) · also on 21 other issuers

Krishna Kolluri is on 26 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Harry Weller

Director, Executive Officer · 7 shared filings (5 issuers) · also on 22 other issuers

Harry Weller is on 27 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Robert Garland

Director · 7 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Richard Rodgers

Executive Officer, Director · 7 shared filings (3 issuers)

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Barbara Dalton

Director · 7 shared filings (4 issuers) · also on 4 other issuers

Barbara Dalton is on 8 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

James Young

Director · 6 shared filings (1 issuer) · also on 4 other issuers

James Young is on 5 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Thomas Beck

Director · 6 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Merdad Parsey

Executive Officer, Director · 6 shared filings (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Timothy B. Lowinger

Executive Officer · 6 shared filings (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

James McArthur

Executive Officer, Director · 6 shared filings (4 issuers) · also on 1 other issuer

James McArthur is on 5 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Christoph M. Adams

Executive Officer, Director · 6 shared filings (4 issuers)

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Ryan Drant

Director · 5 shared filings (3 issuers) · also on 35 other issuers

Ryan Drant is on 38 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

M. James Barrett

Director · 5 shared filings (3 issuers) · also on 4 other issuers

M. James Barrett is on 7 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Patrick J. Kerins

Director · 5 shared filings (3 issuers) · also on 1 other issuer

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

WAYNE FOSTER

Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Leon O. Moulder, Jr.

Executive Officer, Director · 4 shared filings (1 issuer) · also on 6 other issuers

Leon O. Moulder, Jr. is on 7 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

Mary Lynne Hedley

Executive Officer, Director · 4 shared filings (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Michael Raab

Executive Officer, Director · 4 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Ari Helenius

Director · 4 shared filings (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Mette Kirstine Agger

Director · 4 shared filings (3 issuers) · also on 2 other issuers

Mette Kirstine Agger is on 5 issuers in total — a repeat sponsor. Their page lists every one.

No photo found yet (own website and image search run after this page is viewed)

Person

DONALD BERGSTROM

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as David Mott. Their page shows their other deals.

The team behind the deals

Sponsor group

Nea

19 issuers · 27 filings · $10.96B reported sold · 2009–2025

N1 NEA 19 Venture Growth Equity, L.P. Pooled Investment Fund · 2025
NE New Enterprise Associates 19, L.P. Pooled Investment Fund · 2025
N1 NEA 19 Access Fund, L.P. Pooled Investment Fund · 2025
NS NEA SH SPV, L.P. Pooled Investment Fund · $12.5M sold · 2023
NT NEA TS 2024 SPV, L.P. Pooled Investment Fund · $155M sold · 2024
NS NEA Secondary Opportunity Fund, L.P. Pooled Investment Fund · $468.2M sold · 2024
NC NEA CH SPV, L.P. Pooled Investment Fund · $65M sold · 2024
NE New Enterprise Associates 18, L.P. Pooled Investment Fund · $2.85B sold · 2021
N1 NEA 18 Venture Growth Equity, L.P. Pooled Investment Fund · $2.33B sold · 2021
NB NEA BH SPV II, L.P. Pooled Investment Fund · $67.3M sold · 2020
CV Connect Ventures I, L.P. Pooled Investment Fund · 2020
NB NEA BH SPV, L.P. Pooled Investment Fund · $129.3M sold · 2019 · listed
NE New Enterprise Associates 17, L.P. Pooled Investment Fund · 2019 · listed
NE New Enterprise Associates 16, L.P. Pooled Investment Fund · 2017 · listed
N1 NEA 15 Opportunity Fund, L.P. Pooled Investment Fund · $350M sold · 2015 · listed
NE New Enterprise Associates 15, L.P. Pooled Investment Fund · 2015 · listed
NE New Enterprise Associates 14, L.P. Pooled Investment Fund · $2.08B sold · 2012 · listed
N1 NEA 14 Manager Fund, L.P. Pooled Investment Fund · 2012 · listed
NE NEW ENTERPRISE ASSOCIATES 13 LP Pooled Investment Fund · $2.46B sold · 2009 · listed

One team, 19 deal companies. David Mott is listed on 8 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name David Mott.

Sponsor group

Cydan

3 issuers · 4 filings · $22.3M reported sold · 2013–2019

TT Tiburio Therapeutics Inc. Pharmaceuticals · $5M sold · 2019 · listed
C Cydan II, Inc. Biotechnology · $10.7M sold · 2017 · listed
C Cydan, LLC Pharmaceuticals · $6.6M sold · 2013 · listed

One team, 3 deal companies. David Mott is listed on 3 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name David Mott.

Sponsor group

Zosano Pharma

3 issuers · 11 filings · $12.6M reported sold · 2010–2016

ZP Zosano Pharma Corp Pharmaceuticals · $15M sold · 2013
Z ZOSANO, INC. Other · $365K sold · 2013
ZP Zosano Pharma Inc Pharmaceuticals · $39M sold · 2010 · listed

One team, 3 deal companies. David Mott is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name David Mott.

Same business address

51 other issuers file from the same address (first 50 shown)

NEA RP SPV, L.P. Timonium, MD · 2024
NEA DB 2026 SPV-A, L.P. Timonium, MD · 2026
NEA CH 2026 II SPV, L.P. Timonium, MD · 2026
Pi Health Inc. Cambridge, MA · 2024
NEA CH 2026 SPV, L.P. Timonium, MD · 2026
AIS VGP-6, LLC San Mateo, CA · 2016
Caldera Therapeutics, Inc. Cambridge, MA · 2026
NEA 19 Access Fund, L.P. Timonium, MD · 2025
New Enterprise Associates 19, L.P. Timonium, MD · 2025
NEA 19 Venture Growth Equity, L.P. Timonium, MD · 2025
NEA TS 2025 SPV, L.P. Timonium, MD · 2025
Atlas Venture Opportunity Fund Ill, L.P. Cambridge, MA · 2025
NEA SH SPV, L.P. Timonium, MD · 2023
NEA SH 2025 SPV, L.P. Timonium, MD · 2025
Lytica Therapeutics, Inc. Cambridge, MA · 2024
Cognito Therapeutics Group, Inc. Cambridge, MA · 2025
NEA 1F 2025 SPV, L.P. Timonium, MD · 2025
NEA 1M 2025 SPV, L.P. Timonium, MD · 2025
NEA PLA 2025 SPV, L.P. Timonium, MD · 2025
WE Select Fund 2, L.P. Waltham, MA · 2025
WE Select Fund 1, L.P. Waltham, MA · 2025
Atlas Venture Fund XIV, L.P. Cambridge, MA · 2024
Webster StrideCare Co-investment Fund, L.P. Waltham, MA · 2024
Judo Bio Inc. Cambridge, MA · 2022
NEA TS 2024 SPV, L.P. Timonium, MD · 2024
NEA Secondary Opportunity Fund, L.P. Timonium, MD · 2024
Virpax Pharmaceuticals, Inc. Berwyn, PA · 2018
SharpRank, Inc. Timonium, MD · 2021
NEA CH SPV, L.P. Timonium, MD · 2024
Emerson Equity Bridge Fund 1, LLC San Mateo, CA · 2024
Zenas BioPharma, Inc. Waltham, MA · 2022
Webster Equity Partners II-B, L.P. Waltham, MA · 2024
Webster USPP Co-Investment Fund, L.P. Waltham, MA · 2024
Chronus Health, Inc. Fremont, CA · 2019
Webster CVM Co-Investment Fund, L.P. Waltham, MA · 2022
Annovis Bio, Inc. Berwyn, PA · 2010
Axcella Health Inc. Cambridge, MA · 2015
Webster Equity Partners V-B, L.P. Waltham, MA · 2022
Webster Equity Partners V GP, LLC Waltham, MA · 2022
NEA 18 Venture Growth Equity, L.P. Timonium, MD · 2021
New Enterprise Associates 18, L.P. Timonium, MD · 2021
Stride Consumer Fund I, L.P. Waltham, MA · 2020
Stride Family Investments, L.P. Waltham, MA · 2021
Stride Consumer Chomps Coinvest, L.P. Waltham, MA · 2022
Atlas Venture Fund XIII, L.P. Cambridge, MA · 2022
Highway 1 Medical, Inc. San Mateo, CA · 2021
El Camino Real Medical, Inc. San Mateo, CA · 2021
WEBSTER EQUITY PARTNERS V, L.P. Waltham, MA · 2020
Webster Equity Partners IV Bristol CF, L.P. Waltham, MA · 2021
Webster Equity Partners Bristol CF, L.P. Waltham, MA · 2021

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); KY (Kentucky Secretary of State — Business Entity Search (sosbes.sos.ky.gov), searched by issuer name, data as of Oct 24, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

None of the 24 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to David Mott by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 24 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers David Mott is listed on: none on file. No website or social profile named in NEW ENTERPRISE ASSOCIATES 13 LP's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #367,263 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Baltimore, MD). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when David Mott appears on a new Form D, or when a court case or SEC action is matched to them. See plans →

David Mott

The short version

What the community is saying

Key records

1. Lawsuits

2. Regulatory actions

3. Bankruptcies

4. Differences between public sources

20 bankruptcy cases name the subject or team members

David Mott appears on 7 deals that stopped filing before reaching their target

6 Form Ds were filed more than 15 days after the first sale

27 offerings have no amendment in the last 12 months and may still be open

David Mott's role changed at Mersana Therapeutics, Inc.: executive officer, director → director

David Mott's role changed at Mersana Therapeutics, Inc.: director → executive officer, director

6 offerings changed their target amount between filings

David Mott is written 2 different ways on the filings

Reported revenue range changed between filings — TESARO, Inc.

6 address changes between filings

David Mott is listed with 4 different address states: MD, CA, MA, P7

5. Money to insiders

Deals 24

People around David 40

The team behind the deals

51 other issuers file from the same address (first 50 shown)

Registrations and other filings

Business registration (state registry / Secretary of State)

Adviser registration (Form ADV)

Other offering types (Regulation A and Regulation Crowdfunding)

Public profiles and social

Look further

Social and web

Courts

Securities regulators

Business registries

Change history

Request a correction

Add a response

Monitor this person